Lymph-Node-Targeted Immune Activation by Engineered Block Copolymer Amphiphiles-TLR7/8 Agonist Conjugates.
Simon Van HerckKim DeswarteLutz NuhnZifu ZhongJoao Paulo Portela CataniYupeng LiXiaole CuiStefan LienenklausStefaan De KokerBart N LambrechtSunil A DavidBruno G De GeestPublished in: Journal of the American Chemical Society (2018)
Small molecule immuno-modulators such as agonists of Toll-like receptors (TLRs) are attractive compounds to stimulate innate immune cells toward potent antiviral and antitumor responses. However, small molecules rapidly enter the systemic circulation and cause "wasted inflammation". Hence, synthetic strategies to confine their radius of action to lymphoid tissue are of great relevance, to both enhance their efficacy and concomitantly limit toxicity. Here, we demonstrate that covalent conjugation of a small molecule TLR7/8 agonist immunomodulatory to a micelle-forming amphiphilic block copolymer greatly alters the pharmacokinetic profile, resulting in highly efficient lymphatic delivery. Moreover, we designed amphiphilic block copolymers in such a way to form thermodynamically stable micelles through π-π stacking between aromatic moieties, and we engineered the block copolymers to undergo an irreversible amphiphilic to hydrophilic transition in response to the acidic endosomal pH.
Keyphrases
- small molecule
- lymph node
- highly efficient
- immune response
- protein protein
- cancer therapy
- toll like receptor
- oxidative stress
- inflammatory response
- drug release
- drug delivery
- nuclear factor
- sentinel lymph node
- high resolution
- ionic liquid
- radiation therapy
- neoadjuvant chemotherapy
- early stage
- solid phase extraction
- drug induced